BIOCON | BH.IMMUN&BIO | BIOCON / BH.IMMUN&BIO |
|||
---|---|---|---|---|---|
P/E (TTM) | x | 22.6 | -7.8 | - | View Chart |
P/BV | x | 2.1 | 1.5 | 136.0% | View Chart |
Dividend Yield | % | 0.5 | 0.0 | - |
BIOCON BH.IMMUN&BIO |
EQUITY SHARE DATA | |||||
---|---|---|---|---|---|
BIOCON Mar-23 |
BH.IMMUN&BIO Mar-23 |
BIOCON / BH.IMMUN&BIO |
5-Yr Chart Click to enlarge
|
||
High | Rs | 388 | 52 | 748.6% | |
Low | Rs | 192 | 21 | 934.6% | |
Sales per share (Unadj.) | Rs | 93.1 | 10.3 | 900.9% | |
Earnings per share (Unadj.) | Rs | 5.4 | -3.9 | -139.0% | |
Cash flow per share (Unadj.) | Rs | 14.6 | -3.8 | -384.2% | |
Dividends per share (Unadj.) | Rs | 1.50 | 0 | - | |
Avg Dividend yield | % | 0.5 | 0 | - | |
Book value per share (Unadj.) | Rs | 146.5 | 20.4 | 717.3% | |
Shares outstanding (eoy) | m | 1,200.60 | 43.18 | 2,780.5% | |
Bonus / Rights / Conversions | 0 | 0 | - | ||
Price / Sales ratio | x | 3.1 | 3.5 | 89.0% | |
Avg P/E ratio | x | 54.1 | -9.4 | -576.6% | |
P/CF ratio (eoy) | x | 19.8 | -9.5 | -208.6% | |
Price / Book Value ratio | x | 2.0 | 1.8 | 111.7% | |
Dividend payout | % | 28.0 | 0 | - | |
Avg Mkt Cap | Rs m | 347,814 | 1,561 | 22,282.1% | |
No. of employees | `000 | NA | NA | - | |
Total wages/salary | Rs m | 21,810 | 151 | 14,400.8% | |
Avg. sales/employee | Rs Th | 0 | 0 | - | |
Avg. wages/employee | Rs Th | 0 | 0 | - | |
Avg. net profit/employee | Rs Th | 0 | 0 | - |
INCOME DATA | |||||
---|---|---|---|---|---|
Net Sales | Rs m | 111,742 | 446 | 25,049.2% | |
Other income | Rs m | 7,681 | 11 | 72,462.3% | |
Total revenues | Rs m | 119,423 | 457 | 26,149.7% | |
Gross profit | Rs m | 16,611 | -161 | -10,337.3% | |
Depreciation | Rs m | 11,131 | 2 | 556,550.0% | |
Interest | Rs m | 4,190 | 71 | 5,934.8% | |
Profit before tax | Rs m | 8,971 | -223 | -4,028.7% | |
Minority Interest | Rs m | 0 | 0 | - | |
Prior Period Items | Rs m | 0 | 0 | - | |
Extraordinary Inc (Exp) | Rs m | 0 | 0 | - | |
Tax | Rs m | 2,541 | -56 | -4,514.1% | |
Profit after tax | Rs m | 6,430 | -166 | -3,864.4% | |
Gross profit margin | % | 14.9 | -36.0 | -41.3% | |
Effective tax rate | % | 28.3 | 25.3 | 112.0% | |
Net profit margin | % | 5.8 | -37.3 | -15.4% |
BALANCE SHEET DATA | |||||
---|---|---|---|---|---|
Current assets | Rs m | 123,340 | 358 | 34,449.6% | |
Current liabilities | Rs m | 85,107 | 940 | 9,049.9% | |
Net working cap to sales | % | 34.2 | -130.6 | -26.2% | |
Current ratio | x | 1.4 | 0.4 | 380.7% | |
Inventory Days | Days | 129 | 85 | 151.0% | |
Debtors Days | Days | 117 | 1,135 | 10.3% | |
Net fixed assets | Rs m | 394,078 | 1,262 | 31,229.2% | |
Share capital | Rs m | 6,003 | 432 | 1,390.2% | |
"Free" reserves | Rs m | 169,926 | 450 | 37,732.8% | |
Net worth | Rs m | 175,929 | 882 | 19,943.4% | |
Long term debt | Rs m | 152,905 | 0 | - | |
Total assets | Rs m | 517,418 | 1,620 | 31,941.0% | |
Interest coverage | x | 3.1 | -2.2 | -145.8% | |
Debt to equity ratio | x | 0.9 | 0 | - | |
Sales to assets ratio | x | 0.2 | 0.3 | 78.4% | |
Return on assets | % | 2.1 | -5.9 | -34.7% | |
Return on equity | % | 3.7 | -18.9 | -19.4% | |
Return on capital | % | 4.0 | -17.2 | -23.2% | |
Exports to sales | % | 3.1 | 0 | - | |
Imports to sales | % | 6.0 | 14.5 | 41.2% | |
Exports (fob) | Rs m | 3,467 | NA | - | |
Imports (cif) | Rs m | 6,654 | 65 | 10,313.1% | |
Fx inflow | Rs m | 3,467 | 0 | - | |
Fx outflow | Rs m | 6,654 | 65 | 10,313.1% | |
Net fx | Rs m | -3,187 | -65 | 4,939.6% |
CASH FLOW | |||||
---|---|---|---|---|---|
From Operations | Rs m | 18,525 | 109 | 17,007.9% | |
From Investments | Rs m | -142,818 | 5 | -3,091,298.7% | |
From Financial Activity | Rs m | 130,487 | -147 | -88,694.3% | |
Net Cashflow | Rs m | 6,411 | -34 | -19,097.4% |
Indian Promoters | % | 40.4 | 59.3 | 68.1% | |
Foreign collaborators | % | 20.3 | 0.0 | - | |
Indian inst/Mut Fund | % | 19.3 | 0.0 | - | |
FIIs | % | 5.6 | 0.0 | - | |
ADR/GDR | % | 0.0 | 0.0 | - | |
Free float | % | 39.4 | 40.8 | 96.6% | |
Shareholders | 470,261 | 35,313 | 1,331.7% | ||
Pledged promoter(s) holding | % | 0.0 | 0.0 | - |
Compare BIOCON With: DIVIS LABORATORIES CIPLA SUN PHARMA DR. REDDYS LAB ZYDUS LIFESCIENCES
No comparison is complete without understanding how the stock prices have performed over a period of time.
Here's a brief comparison:
Period | Biocon | BH.IMMUN&BIO | S&P BSE HEALTHCARE |
---|---|---|---|
1-Day | -1.17% | -3.30% | -0.31% |
1-Month | 12.47% | 5.32% | -0.40% |
1-Year | 27.03% | 30.40% | 53.30% |
3-Year CAGR | -8.34% | -11.82% | 14.79% |
5-Year CAGR | 0.46% | 31.23% | 19.72% |
* Compound Annual Growth Rate
Here are more details on the Biocon share price and the BH.IMMUN&BIO share price.
Moving on to shareholding structures...
The promoters of Biocon hold a 60.6% stake in the company. In case of BH.IMMUN&BIO the stake stands at 59.3%.
To review how promoter stakes have changed over time, and how much of the promoter stake is pledged, please see the shareholding pattern of Biocon and the shareholding pattern of BH.IMMUN&BIO.
Finally, a word on dividends...
In the most recent financial year, Biocon paid a dividend of Rs 1.5 per share. This amounted to a Dividend Payout ratio of 28.0%.
BH.IMMUN&BIO paid Rs 0.0, and its dividend payout ratio stood at -0.0%.
You may visit here to review the dividend history of Biocon, and the dividend history of BH.IMMUN&BIO.
For a sector overview, read our pharmaceuticals sector report.
Asian stocks got off to a positive start on Monday ahead of the Federal Reserve's policy meeting later in the week.